Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Prostate Neoplasm: early-phase trial registry

6 of 10 indexed Prostate Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 6 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Prostate Neoplasm: 10 US clinical trials tracked, 6 recruiting.

Prostate Neoplasm is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Crozer-Keystone Health System, running 1 of these trials.

Enrollment posture brief

Registry condition prostate-neoplasm

OPEN 6 | RECR 60% | LATE 0 | EARLY 3 | RANK #1724 | SPON 1

Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)

Acute Leukemia of Ambiguous 80%Prostate Neoplasm (this)60%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Prostate Neoplasm

Prostate Neoplasm lists 6 open slots (60% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Prostate Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Prostate Neoplasm is recruiting above its size-band peers.

    6 of 10 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Prostate Neoplasm trials is spread across many organizations.

    Crozer-Keystone Health System accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Typical Prostate Neoplasm enrolment sits around 180 participants.

    Median target enrolment is 180 among the 10 trials that report a genuine target (sentinel values excluded). 3 of those (30%) plan for fewer than 100 participants.

  4. Prostate Neoplasm research is mostly interventional.

    7 interventional and 3 observational studies make up this index (70% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21

Open and recent trials

10 total, page 1 of 1

RECRUITING 8,000 participants

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

UMC Utrecht

NCT04075305

RECRUITING 1,000 participants

Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI

Mayo Clinic

NCT06315595

RECRUITING Phase 1 421 participants

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Eli Lilly and Company

NCT07114601

RECRUITING NA 180 participants

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

University of Chicago

NCT05710380

RECRUITING Phase 2 60 participants

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Shehzad Basaria, M.D.

NCT06957691

RECRUITING Phase 1 36 participants

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

Washington University School of Medicine

NCT03424850

ACTIVE NOT RECRUITING NA 100 participants

CyberKnife Dose Escalation Prostate Cancer Trial

Crozer-Keystone Health System

NCT03822494

ACTIVE NOT RECRUITING 58 participants

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT04030338

COMPLETED NA 188 participants

Health Gatherings - For Your Health After Cancer

University of Miami

NCT03344757

COMPLETED NA 125 participants

Addressing Prostate Cancer Information Disparities With eHealth Technology

Tufts University

NCT02787434

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1

Named interventions

Most-linked intervention names on Prostate Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Prostate Cancer Screening Decision Aid Other
1 trials
Standard CBSM Behavioral
1 trials
Cultural CBSM Behavioral
1 trials
CyberKnife SBRT Radiation
1 trials
PET/CT scan Diagnostic test
1 trials
68Ga-HBED-iPSMA Drug
1 trials
18F-DCFPyL-iPSMA Drug
1 trials
HDR brachytherapy Radiation
1 trials

US sites by state

Facility locations filed on Prostate Neoplasm trials. A trial with sites in several states counts in each.

Massachusetts 3 trials
Texas 2 trials
Pennsylvania 2 trials
New York 2 trials
Missouri 2 trials
Illinois 2 trials
Florida 2 trials
Wisconsin 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Prostate Neoplasm page

10 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Neoplasm condition card totals 10 registered trials; most-linked intervention Prostate Cancer Screening Decision Aid; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.